Non-Cystic Fibrosis Bronchiectasis Treatment Market to Reach USD 3.5 Bn by 2035 at 5.8% CAGR, Driven by rising disease burden ...

Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...

Early diagnosis and treatment in IPF and PPF are vital, as fibrosis is irreversible and current therapies only slow progression. Current IPF treatments, pirfenidone and nintedanib, have significant ...

Delveinsight Strengthens Strategic Decision-Making For IPF Innovators Through Comprehensive Respiratory Domain Conference ...

Elexacaftor-tezacaftor-ivacaftor (ETI) may improve bronchial dilatations in adolescents with cystic fibrosis (CF).

The second round of Inflation Reduction Act negotiation prices, which includes 15 brand-name drugs, will kick into effect in ...

Individuals in close proximity to care for interstitial lung disease (ILD) did not have significantly improved outcomes than those at a greater distance, based on data from more than 1600 individuals ...

For a few moments that evening, the spotlight focused on Ms. Stavros of Pickering, Ont. She was the first in the country who ...

New 6-minute walk test prediction score improves risk assessment in lung disease by combining four key predictors.

The Trump administration is touting $12 billion in federal savings in Medicare’s second year of drug price negotiations.

Inhaled lipid nanoparticles loaded with two medicines reduced IPF lung stiffness and fibrosis in mice, outperforming an ...

Researching IPF after her late husband's diagnosis meant learning many new acronyms and abbreviations, says guest writer.